Bio-Rad partners with Seegene

By staff writers

July 1, 2021 -- Bio-Rad Laboratories announced a partnership with South Korean molecular diagnostics company Seegene to develop and commercialize new diagnostic products for diagnosing infectious diseases.

Seegene will provide diagnostic tests for use on Bio-Rad's CFX96 Dx polymerase chain reaction (PCR) detection system, pending clinical development and clearance from the U.S. Food and Drug Administration, Bio-Rad said.

Seegene's assays offer multiplex real-time PCR detection and differentiation, with high sensitivity and specificity of up to seven targets in a single reaction, according to Bio-Rad.

Bio-Rad's sales rise in Q4, full fiscal year
Bio-Rad Laboratories announced a jump in sales for its fourth quarter and full fiscal year due to increased demand for COVID-19 assays.
Top companies earn 80% of revenue in IVD market
Most of the revenue in the IVD market is generated by fewer than 20 companies, according to a recent report by IVD market research firm Kalorama Information,...
Market for IVD to reach $83.3B
The COVID-19 pandemic is having a dramatic impact on the market, according to Bruce Carlson, Kalorama Information publisher. An upcoming report from Kalorama...
Bio-Rad's Q2 revenue drops
Bio-Rad Laboratories reported that the COVID-19 pandemic negatively impacted its revenue for the second quarter as well as for the first half of the year.

Copyright © 2021

Last Updated ls 7/1/2021 2:08:47 PM

Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current